[go: up one dir, main page]

NO20085422L - Bindingsproteiner for hepatocyttvekstfaktor (HGF) - Google Patents

Bindingsproteiner for hepatocyttvekstfaktor (HGF)

Info

Publication number
NO20085422L
NO20085422L NO20085422A NO20085422A NO20085422L NO 20085422 L NO20085422 L NO 20085422L NO 20085422 A NO20085422 A NO 20085422A NO 20085422 A NO20085422 A NO 20085422A NO 20085422 L NO20085422 L NO 20085422L
Authority
NO
Norway
Prior art keywords
hgf
binding proteins
growth factor
hepatocyte growth
activity
Prior art date
Application number
NO20085422A
Other languages
English (en)
Norwegian (no)
Inventor
May Han
S Kirk Wright
Jr William M Winston
Lyne Breault
Jie Lin
Bijan Etemad-Gilbertson
Christine Knuehl
Jeno Gyuris
Original Assignee
Aveo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals Inc filed Critical Aveo Pharmaceuticals Inc
Publication of NO20085422L publication Critical patent/NO20085422L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20085422A 2006-06-02 2008-12-30 Bindingsproteiner for hepatocyttvekstfaktor (HGF) NO20085422L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81071406P 2006-06-02 2006-06-02
US86046106P 2006-11-21 2006-11-21
PCT/US2007/012950 WO2007143098A2 (fr) 2006-06-02 2007-06-01 Protéines de liaison au facteur de croissance des cellules hépatiques (hgf)

Publications (1)

Publication Number Publication Date
NO20085422L true NO20085422L (no) 2009-02-27

Family

ID=38802082

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085422A NO20085422L (no) 2006-06-02 2008-12-30 Bindingsproteiner for hepatocyttvekstfaktor (HGF)

Country Status (15)

Country Link
US (5) US7659378B2 (fr)
EP (2) EP2029627B1 (fr)
JP (2) JP4560582B2 (fr)
KR (1) KR101196184B1 (fr)
AR (1) AR061170A1 (fr)
AT (1) ATE533787T1 (fr)
AU (1) AU2007254853B2 (fr)
BR (1) BRPI0712223A2 (fr)
CA (1) CA2654019A1 (fr)
ES (1) ES2378097T3 (fr)
IL (2) IL195038A0 (fr)
MX (1) MX2008015138A (fr)
NO (1) NO20085422L (fr)
NZ (1) NZ573819A (fr)
WO (1) WO2007143098A2 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007254853B2 (en) * 2006-06-02 2011-11-17 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
AU2007254942B2 (en) 2006-06-02 2011-10-27 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
JP5931336B2 (ja) 2007-07-02 2016-06-08 オンコメッド ファーマシューティカルズ インコーポレイテッド がんを処置および診断するための組成物および方法
US20090124022A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
US20090123946A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
CN102076355B (zh) 2008-04-29 2014-05-07 Abbvie公司 双重可变结构域免疫球蛋白及其用途
US8101725B2 (en) 2008-05-29 2012-01-24 Galaxy Biotech, Llc Monoclonal antibodies to basic fibroblast growth factor
SG191639A1 (en) * 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AU2009256246B2 (en) 2008-06-03 2013-07-18 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2010002862A2 (fr) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Protéines se liant au récepteur 3 du facteur de croissance des fibroblastes (fgfr3)
AU2009268585C1 (en) * 2008-07-08 2014-10-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
MX2011000117A (es) 2008-07-10 2011-02-25 Toray Industries Composicion farmaceutica para tratamiento y prevencion de cancer.
DK2842573T3 (en) 2008-11-07 2017-10-30 Galaxy Biotech Llc Monoclonal antibodies to fibroblast growth factor receptor 2
CA2743775A1 (fr) * 2008-11-12 2010-05-20 Schering Corporation Intron beta g1-igg pour l'expression d'anti-igf1r augmentee
WO2010119991A2 (fr) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Nouveau procédé de traitement anticancéreux
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
TW201119673A (en) * 2009-09-01 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32948A (es) * 2009-10-15 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN103260639A (zh) 2010-08-26 2013-08-21 Abbvie公司 双重可变结构域免疫球蛋白及其用途
CN103459422A (zh) 2010-11-24 2013-12-18 葛兰素集团有限公司 靶向hgf的多特异性抗原结合蛋白
CN106167526A (zh) 2011-07-15 2016-11-30 昂考梅德药品有限公司 Rspo结合剂和其应用
WO2013078223A1 (fr) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anticorps anti-protéine liant le facteur h et procédés pour les utiliser
WO2013102042A2 (fr) 2011-12-30 2013-07-04 Abbvie Inc. Protéines à double liaison spécifique dirigées contre l'il-13 et/ou l'il-17
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
CA2878868A1 (fr) 2012-07-13 2014-01-16 Austin L. Gurney Agents de liaison des proteines rspo3 et leurs utilisations
HK1212359A1 (en) 2012-11-01 2016-06-10 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
CN105246915A (zh) * 2013-03-14 2016-01-13 奥尔德生物制药公司 Hgf抗体及含有其的组合物
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
WO2015031578A1 (fr) * 2013-08-28 2015-03-05 Abbvie Inc. Dosage de hgf
EP3122900A1 (fr) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
WO2016025797A1 (fr) * 2014-08-15 2016-02-18 Oncomed Pharmaceuticals, Inc. Agents de liaison de rspo1 et leurs utilisations
EP3193935A4 (fr) 2014-09-16 2018-03-21 Oncomed Pharmaceuticals, Inc. Traitement de maladies fibrotiques
EP3209769B1 (fr) 2014-10-24 2020-08-05 The Board of Trustees of the Leland Stanford Junior University Compositions et procédés pour induire la phagocytose de cellules positives de classe i du cmh et pour contrer la résistance aux agents anti-cd47/sirpa
WO2016065245A1 (fr) 2014-10-24 2016-04-28 Incept, Llc Échafaudage extraluminal
WO2016094881A2 (fr) 2014-12-11 2016-06-16 Abbvie Inc. Protéines de liaison à lrp-8
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2016205566A1 (fr) * 2015-06-16 2016-12-22 The Regents Of The University Of California Anticorps spécifiques anti-fzd7 et vaccins pour traiter le cancer et réguler la fonction de cellules souches
CA3039910A1 (fr) * 2016-03-28 2017-10-05 The Regents Of The University Of California Anticorps anti-ryk et leurs procedes d'utilisation
NL2017267B1 (en) * 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
BR112019025583A2 (pt) 2017-06-05 2020-06-16 Janssen Biotech, Inc. Anticorpos multiespecíficos geneticamente modificados e outras proteínas multiméricas com mutações assimétricas na região ch2-ch3
CA3067351A1 (fr) * 2017-06-15 2018-12-20 Nai-Kong Cheung Anticorps anti-l1-cam et leurs utilisations
CN118667812A (zh) 2017-12-06 2024-09-20 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
WO2019217450A1 (fr) * 2018-05-08 2019-11-14 Rhode Island Hospital Anticorps anti-chi3l1 pour la détection et/ou le traitement d'une stéatose hépatique non alcoolique / stéatohépatite non alcoolique et des complications subséquentes
JP2022525703A (ja) * 2019-03-20 2022-05-18 ジャベリン・オンコロジー・インコーポレイテッド 抗ａｄａｍ１２抗体およびキメラ抗原受容体、ならびにそれを含む組成物および方法
EP4013869A1 (fr) 2019-08-12 2022-06-22 InteRNA Technologies B.V. Nouveaux traitements impliquant le miarn-193a
CN115461461A (zh) 2020-02-28 2022-12-09 因特尔纳技术有限公司 用于促进免疫原性细胞死亡的miRNA-193a
JP7748962B2 (ja) 2020-03-27 2025-10-03 アビディティー バイオサイエンシーズ，インク． 筋ジストロフィーを処置するための組成物および方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE69233204T2 (de) 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
US7459536B1 (en) * 1999-11-09 2008-12-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HGF-SF monoclonal antibody combinations
WO2004006955A1 (fr) 2001-07-12 2004-01-22 Jefferson Foote Anticorps super humanises
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) * 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
RS53476B (sr) 2003-07-18 2014-12-31 Amgen Fremont Inc. Sredstva za specifično vezivanje faktora rasta hepatocita
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
JP2008545753A (ja) 2005-06-02 2008-12-18 ギャラクシー バイオテック， エルエルシー 抗体で脳腫瘍を処置する方法
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
AU2007254853B2 (en) * 2006-06-02 2011-11-17 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
AU2007254942B2 (en) 2006-06-02 2011-10-27 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
KR100829972B1 (ko) * 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법

Also Published As

Publication number Publication date
US8268315B2 (en) 2012-09-18
ES2378097T3 (es) 2012-04-04
IL195038A0 (en) 2011-08-01
AU2007254853B2 (en) 2011-11-17
US20130203970A1 (en) 2013-08-08
WO2007143098A3 (fr) 2008-06-12
KR20090026315A (ko) 2009-03-12
JP4560582B2 (ja) 2010-10-13
JP5528246B2 (ja) 2014-06-25
AR061170A1 (es) 2008-08-06
EP2029627A2 (fr) 2009-03-04
US20110236377A1 (en) 2011-09-29
JP2009539348A (ja) 2009-11-19
BRPI0712223A2 (pt) 2012-07-10
MX2008015138A (es) 2009-01-28
EP2029627B1 (fr) 2011-11-16
KR101196184B1 (ko) 2012-11-01
JP2010246565A (ja) 2010-11-04
EP2380908A1 (fr) 2011-10-26
US20140178934A1 (en) 2014-06-26
NZ573819A (en) 2011-09-30
WO2007143098A2 (fr) 2007-12-13
IL219655A0 (en) 2012-06-28
US8575318B2 (en) 2013-11-05
CA2654019A1 (fr) 2007-12-13
US20100173361A1 (en) 2010-07-08
WO2007143098A8 (fr) 2009-01-08
AU2007254853A1 (en) 2007-12-13
US7659378B2 (en) 2010-02-09
AU2007254853A2 (en) 2009-02-12
US20080038257A1 (en) 2008-02-14
HK1129394A1 (en) 2009-11-27
ATE533787T1 (de) 2011-12-15
US7935502B2 (en) 2011-05-03

Similar Documents

Publication Publication Date Title
NO20085422L (no) Bindingsproteiner for hepatocyttvekstfaktor (HGF)
NO20085421L (no) Bindingsproteiner for hepatocyttvekstfaktor (HGF)
WO2019032662A8 (fr) Agents de liaison à clec9a et utilisations associées
WO2008065378A3 (fr) Composés
NO20074446L (no) DR5-antistoffer og anvendelser derav
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
DK2269656T3 (da) Udvalgte antistoffer, som binder til aminophospholipider og deres anvendelse i behandling, så som cancer
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
NO20091413L (no) WNT-antagonister og deres anvendelse i diagnostiseringen og behandlingen av WNT-medierte forstyrrelser
BR112013010857A2 (pt) imonoglubulinas de duplo domínio variável e usos das mesmas
NO20084374L (no) Imidazoltiazolforbindelser for behandling av sykdom
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
MX2010003117A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
PH12013500355A1 (en) Engineered anti-tslp antibody
NO20072461L (no) Fremstilling og anvendelse av bifenyl-4-yl-karbonylaminosyre derivater for behandling av fedme
EP2118123A4 (fr) Peptides p53 stabilises et utilisations de ceux-ci
WO2009026657A8 (fr) Agonistes flavonoïdes de ppar
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
BRPI0615270A2 (pt) pirazol fundido como inibidores de p38 map cinase
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
WO2007076161A3 (fr) Composés ayant une activité thérapeutique
EP2175879A4 (fr) Traitement de maladies associées à la protéine prion
DK3806895T3 (da) Antistoffer der binder tumorvæv, og deres diagnostiske og terapeutiske anvendelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application